Teachers Advisors LLC increased its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 209,027 shares of the medical equipment provider’s stock after buying an additional 3,438 shares during the period. Teachers Advisors LLC owned about 0.20% of MiMedx Group worth $1,852,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in MDXG. Russell Investments Group Ltd. bought a new stake in MiMedx Group during the fourth quarter valued at $5,541,000. Cutter & CO Brokerage Inc. bought a new stake in MiMedx Group during the fourth quarter valued at $170,000. Comerica Bank increased its stake in MiMedx Group by 5.5% in the fourth quarter. Comerica Bank now owns 107,442 shares of the medical equipment provider’s stock valued at $942,000 after buying an additional 5,568 shares in the last quarter. State Street Corp increased its stake in MiMedx Group by 7.6% in the fourth quarter. State Street Corp now owns 3,046,408 shares of the medical equipment provider’s stock valued at $26,992,000 after buying an additional 215,108 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in MiMedx Group by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 51,071 shares of the medical equipment provider’s stock valued at $453,000 after buying an additional 2,872 shares in the last quarter. 55.77% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Shares of MiMedx Group, Inc (NASDAQ:MDXG) traded up 1.28% during midday trading on Friday, hitting $15.06. 2,243,561 shares of the company were exchanged. MiMedx Group, Inc has a 52-week low of $6.94 and a 52-week high of $15.60. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 107.57 and a beta of 1.35. The company has a 50-day moving average price of $14.22 and a 200-day moving average price of $10.29.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Friday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.07. MiMedx Group had a return on equity of 12.25% and a net margin of 5.72%. The company had revenue of $72.60 million during the quarter, compared to the consensus estimate of $72.60 million. During the same period last year, the business earned $0.04 EPS. The business’s quarterly revenue was up 36.1% on a year-over-year basis. On average, analysts forecast that MiMedx Group, Inc will post $0.30 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/06/16/teachers-advisors-llc-boosts-position-in-mimedx-group-inc-mdxg-updated-updated.html.

Several analysts have recently commented on the stock. First Analysis downgraded shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 price objective on the stock. in a report on Tuesday, May 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of MiMedx Group in a research note on Wednesday, April 26th. TheStreet upgraded shares of MiMedx Group from a “c+” rating to a “b” rating in a research note on Thursday, March 16th. Zacks Investment Research upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Tuesday, February 21st. Finally, Piper Jaffray Companies started coverage on shares of MiMedx Group in a research report on Friday, March 3rd. They set an “overweight” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $12.00.

In other news, insider William Charles Taylor sold 26,571 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $13.74, for a total transaction of $365,085.54. Following the completion of the sale, the insider now directly owns 533,612 shares of the company’s stock, valued at approximately $7,331,828.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.40% of the stock is owned by company insiders.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.